Concepedia

A cost analysis of upfront DPYD genotype–guided dose individualisation in fluoropyrimidine-based anticancer therapy

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man, Didier Meulendijks, Geert Frederix, Emma Kienhuis, Geert-Jan Creemers, Arnold Baars, Vincent O. Dezentjé, Alexander L.T. Imholz,

European Journal of Cancer · 2018 · 90 citations · 9 references

DOIFull text

Open access

Concepts

References

9

Comparison of Oral Capecitabine Versus Intravenous Fluorouracil Plus Leucovorin as First-Line Treatment in 605 Patients With Metastatic Colorectal Cancer: Results of a Randomized Phase III Study

Paulo M. Hoff, Rafat Ansari, Gerald Batist et al. · Journal of Clinical Oncology · 2001 · 1.1K citations

, , +14

Oral Capecitabine Compared With Intravenous Fluorouracil Plus Leucovorin in Patients With Metastatic Colorectal Cancer: Results of a Large Phase III Study

Eric Van Cutsem, Chris Twelves, Jim Cassidy et al. · Journal of Clinical Oncology · 2001 · 1K citations

, , +14

DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis

Linda M. Henricks, Carin A.T.C. Lunenburg, Femke M. de Man et al. · The Lancet Oncology · 2018 · 419 citations · Full text

, , +16

Upfront Genotyping of <i>DPYD</i>*<i>2A</i> to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis

Maarten J. Deenen, Didier Meulendijks, Annemieke Cats et al. · Journal of Clinical Oncology · 2015 · 345 citations · Full text

, , +17

Increased Prevalence of Dihydropyrimidine Dehydrogenase Deficiency in African-Americans Compared with Caucasians

Lori K. Mattison, Jeanne Fourie, Renée A. Desmond et al. · Clinical Cancer Research · 2006 · 174 citations

, , +11